Pre-made Faricimab benchmark antibody ( Bispecific mAb, anti-VEGFA;ANGPT2 therapeutic antibody, Anti-VPF/VEGF/MVCD1;AGPT2/ANG2/LMPHM10 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-204
Awaiting product image

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-204 Category Tags ,

For more than 100mg, click here for inquiry. >>

inquire

Product Details

Pre-Made Faricimab biosimilar, Bispecific mAb, Anti-VEGFA;ANGPT2 Antibody: Anti-VPF/VEGF/MVCD1;AGPT2/ANG2/LMPHM10 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Faricimab (INN) is a bispecific monoclonal antibody that is being investigated for diabetic macular edema.

Products Name (INN Index)

Pre-Made Faricimab biosimilar, Bispecific mAb, Anti-VEGFA;ANGPT2 Antibody: Anti-VPF/VEGF/MVCD1;AGPT2/ANG2/LMPHM10 therapeutic antibody
INN Name

Faricimab
Target

VEGFA,ANGPT2
Format

Bispecific mAb
Derivation

Bispecific antibody
Species Reactivity

Human
CH1 Isotype

IgG1
VD LC

Kappa,Lambda
Highest_Clin_Trial (Jan '20)

Preregistration
Est. Status

Active
100% SI Structure

1cz8:HL:YX;None
99% SI Structure

None;None
95-98% SI Structure

1bj1:HL:KJ/6bft:AB:HL;4iml:AB:HL/4imk:AD:BC
Year Proposed

2017
Year Recommended

2018
Companies

Chugai Pharmaceutical,Roche
Conditions Approved

NA
Conditions Active

Diabetic macular oedema,Wet age-related macular degeneration,Retinal oedema
Conditions Discontinued

NA
Development Tech

Dual-Affinity?Re-targenting (DART?)
Previous Name

NA
Gm Offical Target Name

VEGFA,ANGPT2
Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide